U.S. FDA Approves Mylan and Biocon’s Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers
BENGALURU, India Dec. 1, 2017 -- Mylan N.V.(NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced...